Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis
Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Study B7451005 is a Phase 2 study which will assess the efficacy and safety of PF-04965842 in
patients with moderate to severe psoriasis. The study will include three PF-04965842 groups
(200 mg daily, 400 mg daily and 200 mg twice daily) and a placebo group. The treatment period
will be 4 weeks in duration and will be followed up by a 4 week follow up period.